10-Q: Enzon Pharmaceuticals Reports Q2 Loss, Merger Dilution

Enzon Pharmaceuticals reported a net loss for Q2 2025, with cash declining, and detailed significant shareholder dilution and NOL limitations from its pending merger with Viskase.

Summary

• Enzon Pharmaceuticals, Inc. (Enzon) reported a net loss of $990,000 for the three months ended June 30, 2025, compared to a net income of $276,000 for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $1,514,000, a significant increase from a net income of $596,000 in the prior year period.
• The company had no royalty and milestone revenues in Q2 and YTD 2025, down from $26,000 in both periods in 2024.
• Interest and dividend income decreased by 17% to $501,000 for Q2 2025 and by 20% to $998,000 for YTD 2025, primarily due to reduced cash balances and lower interest rates.
• General and administrative expenses increased by 19% to $809,000 for the six months ended June 30, 2025, mainly due to professional and consulting fees.
• Transaction expenses related to the Viskase merger were $1,219,000 for Q2 2025 and $1,726,000 for YTD 2025, with no comparable amounts in 2024.
• Cash and cash equivalents decreased by $2,565,000, from $46,859,000 at December 31, 2024, to $44,294,000 at June 30, 2025.
• The company's Section 382 Rights Agreement, previously set to expire on June 30, 2026, was amended to expire on September 30, 2025, as required by the Merger Agreement.
• Upon closing of the merger with Viskase, current Enzon common stockholders are expected to own approximately 2.0% of the combined company, Series C Preferred stockholders 13.9%, and Viskase stockholders 84.1%.
• The merger is expected to trigger an ownership change under IRC Section 382, which will substantially limit Enzon's ability to utilize its Net Operating Losses (NOLs) and R&D tax credit carryforwards.
• Enzon's stock was delisted from OTCQX to OTCQB on August 12, 2025, after its bid price fell below $0.10 for 30 consecutive days.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant financial losses, declining cash, the delisting of the stock to a lower tier, and the severe dilution expected for current common shareholders post-merger. While the merger provides a strategic path forward, its terms are highly unfavorable for existing common equity holders, and the impairment of NOLs further diminishes potential future value.

Positives

• The Federal Trade Commission granted early termination of the Hart-Scott-Rodino waiting period for the Viskase merger on July 15, 2025, removing a regulatory hurdle.
• The Merger Agreement has been unanimously recommended by Enzon's Special Committee and a Special Committee of Viskase's independent directors, and unanimously approved by both Boards of Directors.
• A partial reversal of the valuation allowance for deferred tax assets was recorded, indicating management's projection of future taxable income through the expected merger closing date.

Negatives

• Enzon reported a net loss of $990,000 for Q2 2025 and $1,514,000 for YTD 2025, a significant decline from net income in the prior year periods.
• The company generated no royalty or milestone revenues in Q2 and YTD 2025, indicating a lack of operational income from its historical business.
• Cash and cash equivalents decreased by $2,565,000 during the first six months of 2025, driven by operating losses and preferred stock dividend payments.
• Interest and dividend income declined by 17% in Q2 2025 and 20% in YTD 2025, reflecting reduced cash balances and lower interest rates.
• Significant transaction expenses of $1,726,000 were incurred for the six months ended June 30, 2025, related to the Viskase merger.
• The company's stock was delisted from OTCQX to OTCQB on August 12, 2025, due to its bid price falling below $0.10 for 30 consecutive calendar days, indicating reduced market standing and liquidity.
• The Board did not declare a cash dividend on Series C Preferred Stock for 2025 without Viskase's consent, leading to a 5% accretion of the liquidation preference ($1,062,000 for YTD 2025).
• Current Enzon common stockholders are expected to experience significant dilution, owning only approximately 2.0% of the combined company post-merger.

Risks

• The conditions to the closing of the Merger may not be satisfied, including the failure to obtain necessary stockholder approvals.
• Uncertainties exist regarding the timing of the consummation of the Merger and the ability of each party to complete the transaction.
• Anticipated benefits of the proposed transaction, such as cost reductions, revenues, earnings, and growth, may not be realized.
• Possible disruptions from the Merger could harm Enzon's business or the business of the combined company.
• Restrictions during the pendency of the Merger may impact Enzon's ability to pursue certain business opportunities or strategic transactions.
• Enzon may be unsuccessful in its strategy to fully utilize its Net Operating Losses (NOLs) and other tax assets, especially if the Merger is not consummated.
• The Merger is expected to trigger an ownership change under IRC Section 382, which will substantially limit the combined company's ability to utilize its NOLs and R&D tax credit carryforwards, potentially making a majority of them permanently unusable.
• Enzon's sources of revenue are limited, and only limited revenue and profitability are expected for the foreseeable future, primarily from interest on cash reserves.
• Rights to receive royalties on sales of PegIntron and other drug products have expired, and no future royalties from other sources are anticipated.
• Natural disasters, pandemics, or other major public health crises may materially and adversely affect future licensing fees, milestone payments, and royalties.
• Enzon's reallocation of employment responsibilities and outsourcing of corporate functions make it more dependent on third parties.
• The company may be subject to product liability or other claims from past clinical trials, and insurance may not cover all claims.
• Proprietary rights may offer only limited protection against competing products.
• The price of Enzon's common stock has been, and may continue to be, volatile, including after the consummation of the Merger.
• The common stock is quoted on the OTCQB market, which has a very limited trading market and low liquidity, potentially limiting stockholders' ability to sell shares.
• The declaration of dividends is at the discretion of the Board, subject to Delaware corporate law and Series C Preferred Stock requirements, and now requires Viskase's consent.
• The termination of the Section 382 Rights Agreement, required by the Merger Agreement, removes protections against corporate takeovers that could limit NOL utilization.
• Anti-takeover provisions in charter documents and Delaware corporate law may make it more difficult to acquire Enzon.
• The terms of outstanding Series C Preferred Stock and potential issuance of additional preferred stock may adversely affect common stockholders' rights.
• The interests of significant stockholders (Carl C. Icahn, IEH, and their affiliates) may conflict with the interests of other stockholders.
• If a Change of Control occurs (e.g., Merger consummation), holders of Series C Preferred Stock (other than IEH affiliates) have the right to demand redemption, which would negatively impact available cash.
• If the Merger Agreement is terminated or the termination date passes without effect, Enzon may incur substantial costs and adverse effects on its business, financial results, and operations.
• The Merger Agreement is subject to numerous closing conditions, and the Merger may not close as currently structured or at all.

Future Outlook

The merger with Viskase Companies, Inc. is expected to close before the end of the calendar year 2025. Following the merger, Enzon Pharmaceuticals, Inc. anticipates changing its name to Viskase Holdings, Inc., and Viskase will convert into a limited liability company. The company expects its Net Operating Losses (NOLs) to be substantially limited by Section 382 of the Internal Revenue Code post-merger. If the merger does not successfully close, Enzon will continue to be positioned as a public company acquisition vehicle, with existing cash and cash equivalents projected to fund operations through at least August 2026.

Management Comments

• "Enzon Pharmaceuticals, Inc. is positioned as a public company acquisition vehicle, where it can become an acquisition platform."
• "Enzon cannot assure you that it will receive any future royalties or milestone payments."
• "Management of the Company will continue to assess the need for this valuation allowance and will make adjustments when or if appropriate."
• "The Company anticipates that the Merger will result in an ownership change as defined under IRC Section 382."
• "The Company expects the Merger to close by the end of 2025."
• "We believe that our existing cash and cash equivalents on hand will be sufficient to fund our operations, at least, through August 2026."

Industry Context

Enzon Pharmaceuticals has transitioned from a pharmaceutical company with licensing arrangements to a 'public company acquisition vehicle' with no clinical operations and minimal royalty revenues. This strategic shift positions it to acquire other businesses. The pending merger with Viskase Companies, Inc. represents a significant pivot, likely into a different industry given Viskase's business. The company's focus on protecting its Net Operating Losses (NOLs) through a Section 382 Rights Agreement, and the subsequent termination of this agreement due to the merger, highlights a common challenge for companies with substantial tax assets undergoing ownership changes. The delisting from OTCQX to OTCQB reflects a decline in market standing, a trend often seen in companies undergoing significant restructuring or with limited operational activity.

Comparison to Industry Standards

• Enzon's current state as a 'public company acquisition vehicle' with no clinical operations and minimal royalty revenue deviates significantly from typical pharmaceutical industry standards, which are characterized by R&D, drug development, and product sales.
• The expected post-merger ownership structure, where current Enzon common stockholders will own only approximately 2.0% of the combined company, represents an unusually high level of dilution compared to many strategic mergers where existing shareholders often retain a more substantial stake.
• The substantial limitation of Net Operating Losses (NOLs) due to the Section 382 ownership change is a common consequence of significant mergers and acquisitions, particularly for companies with large accumulated losses. While the specific impact depends on the size of the NOLs and the annual limitation, Enzon's situation suggests a material impairment of these tax assets, which is a critical consideration for companies with similar tax profiles.
• The delisting from OTCQX to OTCQB indicates a decline in market quality and liquidity, which is generally below the standards for established public companies, even those in niche or restructuring phases. This move suggests a lower tier of market visibility and investor access compared to peers on major exchanges or even higher OTC tiers.

Corporate Governance

Related Party Transactions

• Icahn Enterprises Holdings L.P. (IEH) and its affiliates are significant stockholders of both Enzon and Viskase. IEH beneficially owned approximately 48.6% of Enzon's common stock, 98.2% of Enzon's Series C Preferred Stock, and 90.2% of Viskase's common stock as of August 12, 2025.
• The Merger Agreement provides for a differentiated exchange of Series C Preferred Stock: shares held by IEH affiliates are required to be exchanged for common stock at a discount to liquidation value, while non-affiliates have the right to exchange at liquidation value.
• Carl C. Icahn, IEH, and their respective affiliates are expected to hold a substantial majority of the voting power of the combined company post-merger, allowing them to exert significant influence over management and strategic direction.

Stakeholder Impact

• **Common Shareholders:** Will experience significant dilution, expected to own only approximately 2.0% of the combined company post-merger, leading to a substantial reduction in influence and potential value erosion. The stock's delisting to OTCQB further reduces liquidity and visibility.
• **Series C Preferred Stockholders:** Affiliates of IEH are required to exchange their shares at a discount, while non-affiliates have the option to exchange at liquidation value, impacting their specific returns and capital structure.
• **Company (Enzon):** Undergoes a fundamental strategic transformation from a pharmaceutical entity to an acquisition vehicle, then to a subsidiary of Viskase Holdings, Inc., with a significant change in business focus and corporate identity.
• **Viskase Companies, Inc.:** Becomes a wholly-owned subsidiary of Enzon (which will be renamed Viskase Holdings, Inc.) and will convert into a limited liability company, gaining access to public market capital and potentially new strategic opportunities.
• **Regulatory Authorities:** The merger involves regulatory approvals (e.g., HSR, already granted), and the company's financial reporting remains subject to SEC oversight.

Next Steps

• Enzon intends to file a registration statement on Form S-4 with the SEC, containing a consent solicitation statement and prospectus for the merger.
• The Merger must be approved by Enzon stockholders.
• The Merger is subject to satisfaction or waiver of other certain closing conditions.
• The Merger is expected to close before the end of the calendar year 2025.
• Following the consummation of the Merger, Enzon Pharmaceuticals, Inc. is anticipated to change its name to Viskase Holdings, Inc.
• Following the Merger, Viskase will be converted into a limited liability company and will operate under the name Viskase Companies, LLC.

Key Dates

Recommendation

The filing reveals a company in a precarious financial state, marked by consistent net losses, declining cash reserves, and a lack of operational revenue. The stock's recent delisting from OTCQX to OTCQB signals deteriorating market standing and liquidity. The proposed merger with Viskase, while a strategic pivot, comes at an extremely high cost to existing common shareholders, who are projected to own only 2.0% of the combined entity, representing severe dilution. Furthermore, the merger will trigger an ownership change under Section 382, substantially limiting the utilization of Enzon's significant Net Operating Losses (NOLs), thereby diminishing a key potential asset. Given the poor financial performance, significant dilution, impairment of tax assets, and reduced market liquidity, a seasoned investor would likely recommend a strong sell to minimize further capital erosion.

Keywords

Enzon Pharmaceuticals, Viskase Companies, Merger Agreement, SEC Filing, 10-Q, Financial Results, Net Operating Losses, NOLs, Section 382, Rights Agreement, Shareholder Dilution, Corporate Acquisition, OTC Markets, Preferred Stock, Financial Performance, Corporate Governance